Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis

29 02 2012

To the Editor:

As the sponsor of all four trials included in a recent systematic review and meta-analysis of corifollitropin alfa, we reviewed the manuscript authored by Youssef and co-workers (1) with great interest. This combined analysis includes two phase II dose-finding trials and two phase III randomized controlled trials.

Related to the OHSS incidence per woman randomized, the authors report on page 3 that the number needed to harm (NNH) is equal to 1. This is an obvious error. If the absolute risk increase is 1% as the authors state, the NNH should have been 100. However, the absolute risk increase is less than 1%. This can be demonstrated by combining the control OHSS rate of 2% (page 3) with the OHSS odds ratio of 1.29 (figure 2C). This gives an Elonva OHSS rate of 2.6%, an increase of 0.6% corresponding to an NNH of 177. In a recent pooled analysis by Tarlatzis (2), only the two phase III randomized controlled trials were included and the odds ratio for OHSS, adjusted for trial, was 1.18 (95%CI 0.81-1.71). Read the rest of this entry »

Advertisements




Re: Follicular steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection

10 11 2010

To the Editor:

We read the article by Lamb et al. (1) with great interest. They proposed to determine whether follicular steroid hormone levels are associated with fertilization outcome after intracytoplasmic sperm injection (ICSI). Oocytes that fertilized normally had higher estradiol and testosterone concentrations compared with those that degenerated with ICSI. Oocytes that fertilized normally had also higher estradiol and progesterone concentrations compared with those that failed to fertilize in the study. Read the rest of this entry »





Low AMH and GnRH-antagonist strategies

28 05 2009

To the Editor:

We read with interest the case report by Tocci reporting a live birth in a woman with a negligible anti-Mullerian hormone (AMH) as defined by an AMH of <3.5 pmol/L (1).  We have previously reported a prospective cohort of 61 women with a median AMH of 3.0 (IQR 2.0 -3.8) pmol/L, where use of antagonist cycles without preprogramming achieved a clinical pregnancy rate of 14.7% per cycle started and a trend towards higher pregnancy rates as compared to agonist cycles [adjusted OR 2.89 (95% CI 0.88 -9.50); p=0.08](2).  Read the rest of this entry »





Comment on “Body mass index is an independent risk factor for the development of endometrial polyps in patients undergoing in vitro fertilization.”

4 03 2009

To the Editor:

We would like to make some comments on the paper by Onalan et al (1). In this paper, the authors found that obesity could be a factor in initiating the growth of an endometrial polyp because they identified obesity as the only independent risk factor using logistic regression analysis. Read the rest of this entry »





Lack of clinical and scientific evidence to justify the systematic use of ICSI in HIV-serodiscordant couples wishing to conceive where the male partner is infected

30 10 2008

 

To the Editor:

 

Sauer et al. (1) reported, in a recent Fertility and Sterility issue, 10 years’ experience of an ICSI program in 181 HIV-serodiscordant couples. One hundred three deliveries were reported. It’s noteworthy that the multiple pregnancy (MP) rate was 41%, and 43% of infants were born preterm. Twenty-one infants weighed less than 1500 grams. No female HIV-seroconversions occurred. Read the rest of this entry »